🇺🇸 HALO — Halozyme Therapeutics, Inc.

Salud Compra
← Volver

Precio actual

103,63 USD

Máx. histórico

131,18

8 días

Caída desde máximo

-21,00%

Rango 52 semanas

61,23 – 134,00

Variación hoy

-15,72%

Cierre anterior

122,96

Rango de hoy

102,53 – 118,26

Volumen hoy

6.161.516

Peor caída histórica

-74,26%

05/06/2007 → 04/12/2008

Recuperado en 1154 días

Volatilidad anualizada ⓘ

58,09%

Información
Nombre completo
Halozyme Therapeutics, Inc.
Divisa
USD
Mercado
NasdaqGS
Sector
Salud
Industria
Biotechnology
Empleados
423
PER ⓘ
30,30 (puede no estar actualizado)
Dividend yield
0,00% (puede no estar actualizado)
Precio objetivo analistas
108,89 USD (puede no estar actualizado)
Primera cotización
16/03/2004
Precio actualizado
hace 12 horas
Sobre la empresa

Halozyme Therapeutics, Inc., a biopharmaceutical company, researches, develops, and commercializes of proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 that facilitates subcutaneous (SC) administration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; and XYOSTED, an injection for SC administration of testosterone replacement therapy. The company also provides Herceptin (trastuzumab) under the brand name Herceptin Hylecta; and Phesgo to treat breast cancer; Mabthera SC for chronic lymphocytic leukemia treatment; Tecentriq SC for IV infusion; Ocrevus SC for multiple sclerosis; HYQVIA to treat primary immunodeficiency disorders; DARZALEX to treat amyloidosis, and smoldering and multiple myeloma; epinephrine Injection to treat allergic reactions; nivolumab and relatlimab to treat metastatic or unresectable melanoma; teriparatide injections; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. It has collaborations and licensing agreements with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc.; Takeda Pharmaceuticals International AG and Baxalta US Inc.; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol Myers Squibb Company; argenx BVBA; ViiV Healthcare; Chugai Pharmaceutical Co., Ltd.; Acumen Pharmaceuticals, Inc.; Merus N.V.; and Skye Bioscience, Inc. The company was founded in 1998 and is headquartered in San Diego, California.

Rentabilidad mensual
Evolución
Histórico día a día
Fecha Apertura Máximo Mínimo Cierre Variación Volatilidad día Volumen
23/03/2011 6,06 6,43 5,96 6,43 +6,11% 7,76% 658.300
22/03/2011 6,23 6,26 5,79 6,06 -2,26% 7,54% 1.326.000
21/03/2011 6,42 6,49 6,16 6,20 -2,05% 5,14% 409.900
18/03/2011 6,36 6,52 6,26 6,33 +0,32% 4,09% 1.894.600
17/03/2011 6,35 6,38 6,24 6,31 +0,80% 2,20% 733.200
16/03/2011 6,26 6,34 6,07 6,26 -0,63% 4,31% 587.000
15/03/2011 6,28 6,40 6,16 6,30 -1,72% 3,82% 306.700
14/03/2011 6,53 6,69 6,40 6,41 -3,46% 4,44% 339.200
11/03/2011 6,79 6,90 6,40 6,64 +2,47% 7,36% 383.800
10/03/2011 6,79 6,80 6,46 6,48 -5,95% 5,01% 362.300
09/03/2011 6,98 6,99 6,81 6,89 -1,15% 2,58% 235.000
08/03/2011 6,65 6,98 6,56 6,97 +4,50% 6,32% 268.500
07/03/2011 6,76 6,78 6,55 6,67 -1,04% 3,40% 250.200
04/03/2011 6,81 6,81 6,53 6,74 -0,59% 4,11% 215.500
03/03/2011 6,81 6,86 6,68 6,78 +0,44% 2,64% 432.000
02/03/2011 6,79 6,86 6,66 6,75 -0,88% 2,95% 225.200
01/03/2011 6,92 6,92 6,74 6,81 -1,45% 2,60% 294.300
28/02/2011 6,92 6,99 6,77 6,91 +0,14% 3,18% 282.300
25/02/2011 6,63 6,95 6,58 6,90 +4,39% 5,58% 278.300
24/02/2011 6,61 6,67 6,43 6,61 +0,15% 3,63% 539.800
23/02/2011 6,85 6,87 6,60 6,60 -3,23% 3,94% 327.500
22/02/2011 6,75 6,93 6,67 6,82 -0,29% 3,85% 429.700
18/02/2011 7,03 7,03 6,80 6,84 -2,01% 3,27% 310.000
17/02/2011 7,00 7,08 6,90 6,98 -0,29% 2,57% 241.500
16/02/2011 6,96 7,00 6,80 7,00 +0,86% 2,87% 413.900
15/02/2011 6,95 6,99 6,88 6,94 -0,72% 1,58% 268.500
14/02/2011 6,97 7,04 6,97 6,99 +0,00% 1,00% 226.900
11/02/2011 7,04 7,09 6,97 6,99 -0,99% 1,70% 241.900
10/02/2011 6,95 7,06 6,95 7,06 +1,00% 1,58% 274.600
09/02/2011 7,09 7,21 6,95 6,99 -2,10% 3,67% 243.600